Myeloablative Allo Stem Cell Transplant

Myeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematological Disorders

What's the purpose of the trial?

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation) followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Trial status

Accepting patients

Phase
Phase 2
Enrollment
300
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Allogeneic Stem Cell Transplant
  • Busulfan
  • Cyclophosphamide
  • Fludarabine
  • Mycophenolate Mofetil
  • Radiation
  • Tacrolimus
  • Total Body Irradiation

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.